Potential use of plasma β-amyloid (Aβ)42/Aβ40 to identify amyloidosis


  • Plasma Aβ42/Aβ40 measured by immunoprecipitation mass spectrometry (IPMS) can be used to screen cognitively normal people for amyloidosis accurately.

Why this matters

  • Amyloid positron emission tomography (PET) scans and cerebrospinal fluid (CSF) tests for Aβ42 and Aβ40 are validated biomarkers for people with Alzheimer’s disease (AD), however, these methods are costly and invasive.

  • An accurate blood test for an AD biomarker would be inexpensive, quick, and useful for preventative clinical trials, however, this is not available.